Pfizer-partnered cancer startup goes public in $143M IPO

Pyxis Oncology, the Longwood Fund spinout focused on solid tumors that scored a licensing deal with Pfizer Inc. (NYSE: PFE) earlier this year, has gone public, raising $143 million in an IPO.
Click here to view original post